vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Mistras Group, Inc. (MG). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $181.5M, roughly 1.4× Mistras Group, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 2.1%, a 9.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 5.1%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $26.0M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -0.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
ANIP vs MG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $181.5M |
| Net Profit | $27.5M | $3.8M |
| Gross Margin | — | 28.4% |
| Operating Margin | 14.1% | 7.0% |
| Net Margin | 11.1% | 2.1% |
| Revenue YoY | 29.6% | 5.1% |
| Net Profit YoY | 367.5% | -27.4% |
| EPS (diluted) | $1.14 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $181.5M | ||
| Q3 25 | $227.8M | $195.5M | ||
| Q2 25 | $211.4M | $185.4M | ||
| Q1 25 | $197.1M | $161.6M | ||
| Q4 24 | $190.6M | $172.7M | ||
| Q3 24 | $148.3M | $182.7M | ||
| Q2 24 | $138.0M | $189.8M | ||
| Q1 24 | $137.4M | $184.4M |
| Q4 25 | $27.5M | $3.8M | ||
| Q3 25 | $26.6M | $13.1M | ||
| Q2 25 | $8.5M | $3.0M | ||
| Q1 25 | $15.7M | $-3.2M | ||
| Q4 24 | $-10.3M | $5.2M | ||
| Q3 24 | $-24.2M | $6.4M | ||
| Q2 24 | $-2.3M | $6.4M | ||
| Q1 24 | $18.2M | $995.0K |
| Q4 25 | — | 28.4% | ||
| Q3 25 | — | 29.8% | ||
| Q2 25 | — | 29.1% | ||
| Q1 25 | — | 25.3% | ||
| Q4 24 | — | 26.5% | ||
| Q3 24 | — | 26.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 25.0% |
| Q4 25 | 14.1% | 7.0% | ||
| Q3 25 | 15.9% | 10.4% | ||
| Q2 25 | 6.6% | 4.5% | ||
| Q1 25 | 13.3% | -0.6% | ||
| Q4 24 | -2.3% | 6.1% | ||
| Q3 24 | -13.8% | 6.5% | ||
| Q2 24 | 3.7% | 6.3% | ||
| Q1 24 | 14.8% | 3.0% |
| Q4 25 | 11.1% | 2.1% | ||
| Q3 25 | 11.7% | 6.7% | ||
| Q2 25 | 4.0% | 1.6% | ||
| Q1 25 | 8.0% | -2.0% | ||
| Q4 24 | -5.4% | 3.0% | ||
| Q3 24 | -16.3% | 3.5% | ||
| Q2 24 | -1.7% | 3.4% | ||
| Q1 24 | 13.2% | 0.5% |
| Q4 25 | $1.14 | $0.12 | ||
| Q3 25 | $1.13 | $0.41 | ||
| Q2 25 | $0.36 | $0.10 | ||
| Q1 25 | $0.69 | $-0.10 | ||
| Q4 24 | $-0.45 | $0.17 | ||
| Q3 24 | $-1.27 | $0.20 | ||
| Q2 24 | $-0.14 | $0.20 | ||
| Q1 24 | $0.82 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $28.0M |
| Total DebtLower is stronger | — | $178.0M |
| Stockholders' EquityBook value | $540.7M | $235.1M |
| Total Assets | $1.4B | $578.8M |
| Debt / EquityLower = less leverage | — | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $28.0M | ||
| Q3 25 | $262.6M | $27.8M | ||
| Q2 25 | $217.8M | $20.0M | ||
| Q1 25 | $149.8M | $18.5M | ||
| Q4 24 | $144.9M | $18.3M | ||
| Q3 24 | $145.0M | $20.4M | ||
| Q2 24 | $240.1M | $17.2M | ||
| Q1 24 | $228.6M | $16.9M |
| Q4 25 | — | $178.0M | ||
| Q3 25 | — | $202.3M | ||
| Q2 25 | — | $189.4M | ||
| Q1 25 | — | $171.9M | ||
| Q4 24 | — | $169.6M | ||
| Q3 24 | — | $189.7M | ||
| Q2 24 | — | $199.7M | ||
| Q1 24 | — | $198.4M |
| Q4 25 | $540.7M | $235.1M | ||
| Q3 25 | $505.8M | $227.4M | ||
| Q2 25 | $436.8M | $215.8M | ||
| Q1 25 | $418.6M | $198.7M | ||
| Q4 24 | $403.7M | $198.6M | ||
| Q3 24 | $405.9M | $205.2M | ||
| Q2 24 | $455.8M | $193.2M | ||
| Q1 24 | $452.0M | $187.1M |
| Q4 25 | $1.4B | $578.8M | ||
| Q3 25 | $1.4B | $596.3M | ||
| Q2 25 | $1.3B | $571.0M | ||
| Q1 25 | $1.3B | $526.8M | ||
| Q4 24 | $1.3B | $523.0M | ||
| Q3 24 | $1.3B | $551.7M | ||
| Q2 24 | $920.8M | $548.1M | ||
| Q1 24 | $914.5M | $542.1M |
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.89× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.85× | ||
| Q3 24 | — | 0.92× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 1.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $32.1M |
| Free Cash FlowOCF − Capex | $29.1M | $26.0M |
| FCF MarginFCF / Revenue | 11.8% | 14.3% |
| Capex IntensityCapex / Revenue | 0.5% | 3.4% |
| Cash ConversionOCF / Net Profit | 1.10× | 8.55× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $8.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $32.1M | ||
| Q3 25 | $44.1M | $4.5M | ||
| Q2 25 | $75.8M | $-9.3M | ||
| Q1 25 | $35.0M | $5.6M | ||
| Q4 24 | $15.9M | $25.7M | ||
| Q3 24 | $12.5M | $19.4M | ||
| Q2 24 | $17.4M | $4.5M | ||
| Q1 24 | $18.3M | $604.0K |
| Q4 25 | $29.1M | $26.0M | ||
| Q3 25 | $38.0M | $-4.1M | ||
| Q2 25 | $71.8M | $-14.7M | ||
| Q1 25 | $32.5M | $1.1M | ||
| Q4 24 | $13.5M | $22.1M | ||
| Q3 24 | $7.7M | $14.6M | ||
| Q2 24 | $13.0M | $-284.0K | ||
| Q1 24 | $13.7M | $-4.2M |
| Q4 25 | 11.8% | 14.3% | ||
| Q3 25 | 16.7% | -2.1% | ||
| Q2 25 | 34.0% | -7.9% | ||
| Q1 25 | 16.5% | 0.7% | ||
| Q4 24 | 7.1% | 12.8% | ||
| Q3 24 | 5.2% | 8.0% | ||
| Q2 24 | 9.4% | -0.1% | ||
| Q1 24 | 10.0% | -2.3% |
| Q4 25 | 0.5% | 3.4% | ||
| Q3 25 | 2.7% | 4.4% | ||
| Q2 25 | 1.9% | 2.9% | ||
| Q1 25 | 1.3% | 2.8% | ||
| Q4 24 | 1.3% | 2.1% | ||
| Q3 24 | 3.2% | 2.6% | ||
| Q2 24 | 3.2% | 2.5% | ||
| Q1 24 | 3.3% | 2.6% |
| Q4 25 | 1.10× | 8.55× | ||
| Q3 25 | 1.66× | 0.34× | ||
| Q2 25 | 8.87× | -3.07× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | 4.96× | ||
| Q3 24 | — | 3.02× | ||
| Q2 24 | — | 0.71× | ||
| Q1 24 | 1.00× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MG
Segment breakdown not available.
